Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

NCT ID: NCT00268255

Last Updated: 2013-04-16

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1/PHASE2
• Study Classification: INTERVENTIONAL

Brief Summary

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Gefitinib may make tumor cells more sensitive to radiation therapy. Giving gefitinib together with radiation therapy may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of radiation therapy when given together with gefitinib and to see how well they work in treating patients with inoperable stage I or stage II non-small cell lung cancer.

Detailed Description

OBJECTIVES:

Primary

• Determine the toxicity profile and maximum tolerated dose of radiotherapy when given in combination with gefitinib in patients with previously untreated, medically inoperable stage I or II non-small cell lung cancer. (Phase I)
• Determine the efficacy of gefitinib when given for 6 weeks prior to and concurrent with radiotherapy, in terms of objective response rate (partial and complete response), in these patients.

Secondary

• Determine the 3-month tumor response (complete and partial response) in patients treated with this regimen.
• Determine the 6-week response rate in patients treated with this regimen.
• Determine the local disease control rate (complete and partial response, stable disease) in patients treated with this regimen.
• Determine the local progression-free survival and disease-specific survival (cancer vs co-morbid disease) of patients treated with this regimen.
• Determine the pattern of failure (e.g., local, regional, or distant metastasis) in patients treated with this regimen.
• Determine the acute and late radiation toxic effects to organs at risk in patients treated with this regimen.
• Determine the safety profile of gefitinib in these patients.

OUTLINE: This is an open-label, multicenter, dose-escalation study of radiotherapy.

• Patients receive oral gefitinib once daily for 13 weeks. Patients also undergo radiotherapy 5 days a week for 7 weeks beginning at week 7. Patients continue to receive gefitinib alone after completion of radiotherapy in the absence of disease progression or unacceptable toxicity.

Cohorts of 6-10 patients receive escalating doses of radiotherapy until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 6 patients experience acute dose-limiting toxicity.

• Phase II: Patients receive oral gefitinib as in phase I and radiotherapy at the MTD determined in phase I. After the completion of radiotherapy, patients continue to receive gefitinib in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 1 year.

PROJECTED ACCRUAL: A maximum of 37 patients will be accrued for this study.

Conditions

Non-small Cell Lung Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

gefitinib

Intervention Type: DRUG

adjuvant therapy

Intervention Type: PROCEDURE

enzyme inhibitor therapy

Intervention Type: PROCEDURE

neoadjuvant therapy

Intervention Type: PROCEDURE

protein tyrosine kinase inhibitor therapy

Intervention Type: PROCEDURE

radiation therapy

Intervention Type: PROCEDURE

radiosensitization

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Measurable disease, defined as lesion diameter ≤ 5 cm NOTE: *No evidence of N1 or N2 disease by positron emission tomography (PET) scan or any histological means (mediastinoscopy, thoracotomy, transbronchial, tracheal aspirations, or transesophageal aspiration by endoscopic ultrasound guidance

PATIENT CHARACTERISTICS:

Performance status

• Any performance status

Life expectancy

• At least 1 year

Hematopoietic

• No restrictions

Hepatic

• No restrictions

Renal

• Creatinine ≤ CTC grade 2

Pulmonary

• No clinically active interstitial lung disease
• Chronic, stable, asymptomatic radiographic changes allowed

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective nonhormonal contraception
• No known severe hypersensitivity to gefitinib or any of the excipients of this product
• No other malignancy within the past 5 years except basal cell cancer or carcinoma in situ of the cervix
• No active or uncontrolled infection
• No uncontrolled systemic disease
• No psychiatric illness or other severe medical condition that would preclude study participation

PRIOR CONCURRENT THERAPY:

Chemotherapy

• No prior chemotherapy

Radiotherapy

• No prior radiotherapy to the chest or mediastinum
• No concurrent elective nodal irradiation

Surgery

• Recovered from prior surgery
• No concurrent ophthalmic surgery

Other

• Recovered from all other prior anticancer therapy (alopecia allowed)
• More than 30 days since prior nonapproved or investigational agents
• No concurrent CYP3A4 inducers, including any of the following:
• Phenytoin
• Carbamazepine
• Barbiturates
• Rifampin
• Phenobarbital
• Hypericum perforatum (St. John's wort)
• No concurrent systemic retinoids

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: collaborator

Barbara Ann Karmanos Cancer Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andrew T. Turrisi, MD

Role: STUDY_CHAIR

Barbara Ann Karmanos Cancer Institute

Other Identifiers

WSU-D-2820

Identifier Type: -

Identifier Source: secondary_id

WSU-HIC-100304M1F

Identifier Type: -

Identifier Source: secondary_id

ZENECA-1839US/0258

Identifier Type: -

Identifier Source: secondary_id

CDR0000447160

Identifier Type: -

Identifier Source: org_study_id